Pre-Conference Workshops

November 28, 2023

Workshop A
8:00 AM-10:30AM

Diving Into Alternative Inflammasomes to Target Beyond NLRP3: Exploring Upstream & Downstream Components of the Inflammasome Pathway


Join this interactive deep dive session where we will explore inflammasomes beyond NLRP3. Thoroughly examine inflammasome activation, downstream effects, and how different pathways interact. By the end of the session, you will have a comprehensive understanding of how to effectively target and address inflammatory processes.

Session highlights include:

• Assessing the ability to drug the different components of the pathway to navigate target selection

• Debating the therapeutic opportunity of targeting beyond NLRP3 and assessing NLRP1, NLRPC4, ASC, and more as the next opportunity

• Navigating the selectivity between inflammasomes to understand the possibilities and to assess the risk or benefit of hitting multiple inflammasomes

• Highlighting possible safety and toxicity effects of unselective inflammasome inhibition

• Understanding human genetics and how they affect inflammasome function to uncover the biochemistry of inflammasome and protein regulation

10:30 am Morning Break

Workshop B
11:00 AM to 1:30 PM

Accelerating the Progress of Inflammasome Biomarkers for Target Engagement, Patient Selection & Therapeutic Efficacy

  • Greggory Housler Director, Early Clinical Research & Development Cardiovascular, Renal & Metabolism, AstraZeneca
  • Marianna Rowlands Director, Immunology Therapeutic Area Biomarker Lead, Translational Medicine, Novartis AG
  • Pablo Pelegrin Principal Investigator, BioMedical Research Institute of Murcia 


The perfect opportunity to come together to assess the progress of clinically validated biomarkers for bench-to-bedside translation. An interactive workshop to collaborate and pre-competitively assess inflammasome biomarkers across indications.

Workshop highlights include:

  • Reviewing the current understanding and usability of biomarkers for inflammasome therapeutics to create a foundation and highlight the knowledge gaps
  • Debating whether there could be an inflammasome biomarker for both CNS and peripheral indications to use across therapeutic applications
  • Harnessing and collecting biomarker data across studies to understand which biomarkers are worth the time and investment for in-human studies

1:30 pm Lunch

Workshop C
2:30 PM – 5:00 PM

Assessing Both Peripheral & CNS Disease Selection for Inflammasome Therapeutics with Preclinical Models: Which Patient Population Will Inflammasome Therapeutics Be Most Effective For?

  • Eric Prinssen Expert Clinical Scientist, Roche
  • Harold Hoffman Professor & Chief of the Division of Allergy, Immunology and Rheumatology, University of California San Diego


During this session we will assess disease selection for inflammasome therapeutics, addressing the main remaining questions of where will inflammasome therapeutics be most effective and for which patient population?

Join the session to look at:

  • Harnessing the appropriate preclinical models that are available for inflammatory and autoimmune disease to verify disease applications and understanding which models big pharma want to see data in
  • Standardizing models across the field to overcome the limitations of inflammasome preclinical models
  • Assessing peripheral vs CNS indications to navigate the patient selection
  • Navigating which disease to go for first in a proof-of-concept to understand where to invest in for the first clinical validation
  • Selecting disease through proof-of-concept or deciding to go for the disease with the bigger therapeutic benefit
  • Discussing inflammasomes as the key to unlocking particular diseases to understand approachable and practical therapeutic development targets